Company Data

4D Molecular Therapeutics Inc.

Ticker
FDMT
Current Price
$4.64 -0.64%
Market Cap
$214.5M
Price Target
Refer to Report
Volume
554.7K
52wk Range
$4.405 - $36.25
Advanced Market Data

Overview

4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.

Inbox Intel from Channelchek.

Informed investors make more money. And itā€™s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy